HOOK
HOOKIPA Pharma Inc.0.8660
-0.0160-1.81%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
10.68MP/E (TTM)
-Basic EPS (TTM)
-4.83Dividend Yield
0%Recent Filings
8-K
Stockholders approve asset sale, dissolution
HOOKIPA Pharma stockholders overwhelmingly approved the asset sale to Gilead Sciences under the May 21, 2025 agreement and the company's plan to liquidate and dissolve, both on July 29, 2025. With 95% support for the sale (5.1M for votes) and 94% for dissolution, the path clears for winding down operations. Stockholders will get liquidation proceeds.
8-K
HOOKIPA plans Nasdaq delisting
HOOKIPA Pharma notified Nasdaq on July 18, 2025, of its plan to voluntarily delist its common stock and deregister under the Exchange Act, targeting effectiveness around August 8, 2025, post-Form 25 filing. This cuts reporting costs ahead of a July 29 stockholder vote on selling HB-400 and HB-500 assets to Gilead and dissolving the company. Delisting saves cash. Post-delisting trading may shift OTC, with no market-making assured.
8-K
Sells assets to Gilead, plans dissolution
HOOKIPA inked an asset sale with Gilead on May 21, 2025, offloading HB-400 (HBV) and select HB-500 (HIV) assets for up to $10M cash—$3M at closing, $7M phased post-transfer—while winding down the ongoing HB-500 trial. Board greenlit company dissolution pending stockholder vote; CEO Peters gets severance and bonuses tied to swift liquidation. Proceeds may fund distributions, yet closing hinges on approvals.
10-Q
Q1 FY2025 results
Hookipa Pharma's Q1 revenue from collaborations fell 95% y/y to $2.0M (Gilead only, post-Roche termination), while R&D expenses dropped 36% y/y to $12.9M amid restructuring and program pauses, yielding an operating loss of $17.9M versus prior profit. Cash held steady at $40.3M, with operating cash flow turning positive at $0.1M (derived) thanks to $16.2M in Austrian research incentives received. Restructuring continues, targeting 80% workforce cut by mid-2025. Yet cash burn stays low. Going concern doubt persists without fresh funding.
10-K
FY2024 results
HOOKIPA Pharma narrowed FY2024 net loss to $43.5M from $81.6M y/y, fueled by $43.9M collaboration revenue—up from $20.1M—via accelerated Roche upfront/milestone recognition post-termination and a $5.0M Gilead HIV dosing milestone; R&D fell 20% to $68.5M amid 80% workforce cuts and eseba-vec/HB-300 pauses, prioritizing Phase 1-ready HB-700 KRAS therapy. Q4 restructuring slashed headcount, closed Vienna labs, terminated HB-200 Phase 1/2 (52% ORR with pembro, not efficacy/safety-driven), yielding $2.7M charges but freeing cash runway. Gilead HBV/HIV programs advance to H1/H2 2025 readouts. $39.9M cash signals going concern doubt; workforce upheaval risks execution. Clinical delays from trial halts threaten momentum.
IPO
Employees
Sector
Industry
ARMP
Armata Pharmaceuticals, Inc.
5.72-0.44
ASMB
Assembly Biosciences, Inc.
33.50-1.10
COCP
Cocrystal Pharma, Inc.
0.98-0.04
CUE
Cue Biopharma, Inc.
0.41-0.05
ENTA
Enanta Pharmaceuticals, Inc.
14.85-0.02
GTBP
GT Biopharma, Inc.
0.72+0.09
HCWB
HCW Biologics Inc.
1.78-0.09
INO
Inovio Pharmaceuticals, Inc.
2.32+0.06
PDSB
PDS Biotechnology Corporation
0.90-0.02
VIR
Vir Biotechnology, Inc.
6.48-0.24